Product Information
UCERIS 2 MG RECTAL FOAM is a brand product labeled by Salix Pharmaceuticals Inc., priced at $11.6277 per GM under NDC 65649065103. Its NADAC has been published 386 times since Oct 18, 2017.
FDA first approved this application on Oct 7, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2 mg/1
Manufacturer
Salix Pharmaceuticals Inc.NDC
65649065103
Classification
Brand
Dosage Form
AEROSOL, FOAM
Route
RECTAL
Effective Date
9/17/2025
Active Ingredients
BUDESONIDEApproval Type
New Drug (NDA)
FDA Application
NDA205613FDA Approved
10/7/2014
TE Code
AB
On Market Since
12/1/2014
Pharmacological Classes
Price Statistics
The NADAC for UCERIS 2 MG RECTAL FOAM has been published 386 times since Oct 18, 2017, and over the history we have for it it has risen 49.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.6277 per GM |
|---|---|
| All-time high | $11.7080 (Apr 16, 2025) |
| All-time low | $7.7796 (Oct 18, 2017) |
| Median price | $10.9243 |
| Average price | $10.3550 |
| Largest weekly change | +9.0% (Jan 17, 2018) |
| Weeks tracked | 386 |
| Tracking since | Oct 18, 2017 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-0.4%
5Y
+14.8%
All
+49.5%
Last surveyed Oct 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 19% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Salix Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
budesonide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of UCERIS 2 MG RECTAL FOAM?
The current National Average Drug Acquisition Cost (NADAC) for UCERIS 2 MG RECTAL FOAM, manufactured by Salix Pharmaceuticals Inc., is $11.6277 per GM (NDC 65649065103), effective Oct 1, 2025.
How has the price of UCERIS 2 MG RECTAL FOAM changed over time?
Over the history we have for it, the NADAC for UCERIS 2 MG RECTAL FOAM has risen 49.5%. It has been tracked across 386 weekly CMS publications since Oct 18, 2017.
What are the highest and lowest recorded NADAC prices for UCERIS 2 MG RECTAL FOAM?
Since Oct 18, 2017, the NADAC for UCERIS 2 MG RECTAL FOAM has ranged from a low of $7.7796 (Oct 18, 2017) to a high of $11.7080 (Apr 16, 2025), with a median of $10.9243 per GM.
Are there cheaper alternatives to UCERIS 2 MG RECTAL FOAM?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUDESONIDE 2 MG RECTAL FOAM, is $9.4092 per GM — about 19% below UCERIS 2 MG RECTAL FOAM.
Who manufactures UCERIS 2 MG RECTAL FOAM?
UCERIS 2 MG RECTAL FOAM (NDC 65649065103) is labeled by Salix Pharmaceuticals Inc., and CMS classifies it as a brand product.